#	Pagina
attuale pagina	/open-fp7/projects/88151/index.html

TREAT OA

Translational Research in Europe – Applied Technologies for Osteoarthritis

Coordinatore	KING'S COLLEGE LONDON Organization address address: Strand city: LONDON postcode: WC2R 2LS contact info Titolo: Mr. Nome: Paul Cognome: Labbett Email: send email Telefono: +44 20 7848 8184 Fax: +44 20 7848 8187
Nazionalità Coordinatore	United Kingdom [UK]
Sito del progetto	http://www.treatoa.eu/
Totale costo	16˙673˙604 €
EC contributo	11˙924˙660 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-IP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-01-01 - 2013-06-30

Partecipanti

#	participant	country	role
1	KING'S COLLEGE LONDON Organization address address: Strand city: LONDON postcode: WC2R 2LS contact info Titolo: Mr. Nome: Paul Cognome: Labbett Email: send email Telefono: +44 20 7848 8184 Fax: +44 20 7848 8187	UK (LONDON)	coordinator
2	ACADEMISCH ZIEKENHUIS LEIDEN Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Ms. Nome: Liesbeth Cognome: Dorama Email: send email Telefono: +31 71 5269569 Fax: +31 71 5268275	NL (LEIDEN)	participant
3	ARCARIOS Organization address address: AGORALAAN A BIS city: DIEPENBEEK postcode: 3590 contact info Titolo: Mr. Nome: Guido Cognome: Maertens Email: send email Telefono: 3123951973	BE (DIEPENBEEK)	participant
4	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Organization address address: 's Gravendijkwal 230 city: ROTTERDAM postcode: 3015CE contact info Titolo: Mr. Nome: Jan Willem Cognome: Te Ronde Email: send email Telefono: 31107038425	NL (ROTTERDAM)	participant
5	ISLENSK ERFDAGREINING EHF Organization address address: Sturlugata 8 city: REYKJAVIK postcode: 101 contact info Titolo: Mr. Nome: Gudmundur Cognome: Einarsson Email: send email Telefono: +354 570 1900 Fax: +354 570 1981	IS (REYKJAVIK)	participant
6	KATHOLIEKE UNIVERSITEIT LEUVEN Organization address address: Oude Markt 13 city: LEUVEN postcode: 3000 contact info Titolo: Ms. Nome: Maria Cognome: Vereeken Email: send email Telefono: +32 16 32 65 04 Fax: +32 16 32 65 15	BE (LEUVEN)	participant
7	KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW Organization address address: KLOVENIERSBURGWAL 29 HET TRIPPENHUIS city: AMSTERDAM postcode: 1011 JV contact info Titolo: Mr. Nome: Don Cognome: Van Velzen Email: send email Telefono: +31 30 21 21 863 Fax: +31 30 21 21 865	NL (AMSTERDAM)	participant
8	SYNARC SAS Organization address address: RUE DE MONTBRILLANT 16 city: LYON postcode: 69003 contact info Titolo: Dr. Nome: Patrick Cognome: Garnero Email: send email Telefono: +33 472 68 65 05 Fax: +33 472 68 65 08	FR (LYON)	participant
9	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Mr. Nome: Edward Cognome: Gibbs Email: send email Telefono: +441865 857 212 Fax: +441865 857 213	UK (OXFORD)	participant
10	TiGENIX NV Organization address address: RESEARCHPARK HAASRODE 1724 ROMEINSE STRAAT 12/2 city: LEUVEN postcode: 3001 contact info Titolo: Mr. Nome: Luc Cognome: Dochez Email: send email Telefono: +32 16 39 60 60 Fax: +32 16 39 60 50	BE (LEUVEN)	participant
11	UNIVERSITY OF IOANNINA Organization address address: "LEOFOROS STAVROS S NIARCHOS, PANEPISTIMIOUPOLI IOANNINON" city: IOANNINA postcode: 45110 contact info Titolo: Prof. Nome: George Cognome: Papageorgiou Email: send email Telefono: +30 26 51 09 72 87 Fax: +30 26 51 09 72 00	EL (IOANNINA)	participant

Mappa

Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

disease drugs genetic biochemical diagnostics genes risk modifying oa progression aetiology treatment markers clinical panel diagnosis treat technologies pathways

Obiettivo del progetto (Objective)

'TREAT-OA will address the need for better treatment and diagnostics for osteoarthritis (OA) - the most common cause of disability in Europe. Currently there are no drugs that can cure, reverse or halt the disease. Nor are there yet reliable clinical biochemical markers for diagnosis or prognosis which is an impediment to the management of OA, costs of therapeutic trials and the development of disease modifying drugs. TREAT-OA represents a large-scale collaborative, integrated, trans-disciplinary project utilising a resource of 28,000 OA phenotyped subjects with available genome-wide association scan data as well as leading basic science laboratories and technologies. This is the largest study of its kind that will address the generalisability and utility of genetic and biochemical risk factors throughout the EU. The key objectives of TREAT-OA are to: 1 Identify genes and biochemical markers consistently associated with risk and progression of OA 2 Use such genes to further our understanding of the molecular pathways involved in disease aetiology 3 Analyze pathways to identify targets for pharmacological intervention 4 Develop transgenic animal laboratory OA model systems . 5 Develop a panel of genetic and biochemical diagnostics for risk and progression of OA 6 Disseminate results from this extensive research at large and use results and technologies for training within the EU TREAT-OA will help develop European clinical and scientific excellence in the diagnosis and treatment of OA. The novel pathways in disease aetiology discovered will translate into novel drug targets and protein therapeutics for OA. The development of in vitro and in vivo assays will provide a comprehensive technology platform enabling the discovery and development of disease modifying drugs for OA. TREAT-OA will also make a major impact on the disease via a diagnostic panel of genes and biochemical markers for selecting severe cases and rapidly progressing individuals.'